The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings

WHO has proposed a public-health approach to antiretroviral therapy (ART) to enable scaling-up access to treatment for HIV-positive people in developing countries, recognising that the western model of specialist physician management and advanced laboratory monitoring is not feasible in resource-poor settings. In this approach, standardised simplified treatment protocols and decentralised service delivery enable treatment to be delivered to large numbers of HIV-positive adults and children through the public and private sector. Simplified tools and approaches to clinical decision-making, centred on the "four Ss"--when to: start drug treatment; substitute for toxicity; switch after treatment failure; and stop--enable lower level health-care workers to deliver care. Simple limited formularies have driven large-scale production of fixed-dose combinations for first-line treatment for adults and lowered prices, but to ensure access to ART in the poorest countries, the care and drugs should be given free at point of service delivery. Population-based surveillance for acquired and transmitted resistance is needed to address concerns that switching regimens on the basis of clinical criteria for failure alone could lead to widespread emergence of drug-resistant virus strains. The integrated management of adult or childhood illness (IMAI/IMCI) facilitates decentralised implementation that is integrated within existing health systems. Simplified operational guidelines, tools, and training materials enable clinical teams in primary-care and second-level facilities to deliver HIV prevention, HIV care, and ART, and to use a standardised patient-tracking system.

[1]  R. Horton,et al.  Public health in the new era: improving health through collective action , 2004, The Lancet.

[2]  S. Swaminathan,et al.  Increasing Nevirapine Dose Can Overcome Reduced Bioavailability Due to Rifampicin Coadministration , 2006, Journal of acquired immune deficiency syndromes.

[3]  Anthony D Harries,et al.  Supervision, monitoring and evaluation of nationwide scale-up of antiretroviral therapy in Malawi. , 2006, Bulletin of the World Health Organization.

[4]  I. James,et al.  Recovery of CD4+ T Cells in HIV Patients With a Stable Virologic Response to Antiretroviral Therapy Is Associated With Polymorphisms of Interleukin-6 and Central Major Histocompatibility Complex Genes , 2006, Journal of acquired immune deficiency syndromes.

[5]  P. Kaleebu,et al.  Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa , 2006, AIDS.

[6]  James Curran,et al.  Scaling Up Antiretroviral Therapy in Resource-Limited Settings: Treatment Guidelines for a Public Health Approach , 2005 .

[7]  I. Bates,et al.  Evaluation of microscope condition in Malawi. , 2000, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[8]  Bg Gazzard and British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. , 2005, HIV medicine.

[9]  Guilbert Jj The World Health Report 2006: working together for health. , 2006 .

[10]  C. Gilks,et al.  National adult antiretroviral therapy guidelines in resource-limited countries: concordance with 2003 WHO guidelines? , 2006, AIDS.

[11]  C. Duncombe,et al.  Guidelines on co-trimoxazole prophylaxis for HIV-related infections among children adolescents and adults. Recommendations for a public health approach. , 2006 .

[12]  A. Huitema,et al.  Indinavir/ritonavir‐based therapy in HIV‐1‐infected antiretroviral therapy‐naive patients: comparison of 800/100 mg and 400/100 mg twice daily , 2005, HIV medicine.

[13]  J. Sterne,et al.  Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries , 2006, The Lancet.

[14]  Christopher D Pilcher,et al.  Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. , 2004, The New England journal of medicine.

[15]  N. Ford,et al.  Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment , 2006, The Lancet.

[16]  J. Gallant,et al.  Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. , 2005, The Journal of infectious diseases.